Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Core Insights - Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions [1][3] - The lead investigational product, tegoprubart, is an anti-CD40L antibody targeting the CD40 Ligand, which plays a significant role in immune cell activation [1][3] - Eledon is conducting preclinical and clinical studies in areas such as kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) [1][3] Company Overview - Eledon Pharmaceuticals is headquartered in Irvine, California [1] - The company is listed on NASDAQ under the ticker symbol ELDN [2] Upcoming Events - Eledon management will host one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 9, 2024, in Boston, MA [2]